SCHEMBL5443075

SCHEMBL5443075

Cc1cc(=O)n(Cc2ccc(Cl)cc2F)cc1-c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.49
▸ TP53 P04637 2/20 0.42
▸ HTR1A P08908 1/20 0.42
▸ HTR2A P28223 1/20 0.42
▸ HTR7 P34969 1/20 0.42
▸ HTR6 P50406 1/20 0.42
▸ POLB P06746 1/20 0.39
▸ PTGDR2 Q9Y5Y4 3/20 0.39
▸ LMNA P02545 2/20 0.38
▸ BRD4 O60885 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ PPARG P37231 1/20 0.37
▸ CHRM1 P11229 2/20 0.37
▸ NR1H2 P55055 1/20 0.36
▸ NR1H3 Q13133 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5447828 0.86 MAPT (0.40) MAPTTP53HTR1AHTR7MEN1
SCHEMBL5197080 0.75 NLRP3 (0.43) MAPTTP53HTR1AHTR7POLB
SCHEMBL5198153 0.73 MAPT (0.39) MAPTTP53HTR1AHTR7PTGDR2
SCHEMBL5184225 0.71 MAPT (0.55) MAPTTP53HTR1AHTR2AHTR7
SCHEMBL14893078 0.71 MAPT (0.55) MAPTTP53HTR1AHTR2AHTR7
SCHEMBL5433829 0.71 MAPT (0.46) MAPTTP53HTR1AHTR2AHTR7
SCHEMBL5442642 0.71 MAPT (0.51) MAPTTP53HTR1AHTR2AHTR7
SCHEMBL5435948 0.70 MAPT (0.45) MAPTPTGDR2BRD4
SCHEMBL5197594 0.70 MAPT (0.57) MAPTTP53HTR1AHTR2AHTR7
SCHEMBL5440757 0.70 MAPT (0.53) MAPTTP53HTR1AHTR2AHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130109652-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS ADDEX PHARMACEUTICALS S.A. (CH) 2013-05-02 — — US disclosed
US-8399493-B2 Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors Janssen Pharmaceuticals, Inc. (US) 2013-03-19 — — US disclosed
US-20070213323-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS Janssen Pharmaceuticals, Inc. 2007-09-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213323-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS GRM2, GRM1, GRM3 MAPT 2615/4885TP53 4883/4885HTR1A 40/4885
US-20130109652-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS GRM2, GRM1, GRIA2 MAPT 2062/4885TP53 4883/4885HTR1A 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback